trial_id	eligibility_criteria
ACTRN12617001190392	NOT KRAS:oncogenic_mutation; NOT NRAS:oncogenic_mutation
ACTRN12619001185156	*(CCNE1:amplification OR CCNE1:overexpression); *catype:High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum; catype:Ovarian cancer
ACTRN12621000507886	catype:lymphoma; catype:B-cell lymphoma
ACTRN12621000639820	(catype:Endometrial cancer OR catype:Ovarian cancer OR catype:Fallopian tube carcinoma OR catype:Peritneal serous carcinoma OR catype:Endometrial stromal sarcoma OR catype:Uterine leiomyosarcoma OR catype:Granulosa cell tumour)
ACTRN12622000973718	catype:Non-small cell lung cancer; KRAS:G12C
ACTRN12623000096651	(catype:Low-grade glioma OR catype:Anaplastic astrocytoma)
NCT02628067	catype:Anal Cancer
NCT02628067	catype:Biliary Tract Cancer
NCT02628067	catype:Cervical Cancer
NCT02628067	catype:Colorectal cancer; NOT microsatellite_instability:high; NOT mismatch_repair:deficient
NCT02628067	catype:Endometrial Carcinoma
NCT02628067	catype:Lung Neuroendocrine Tumor
NCT02628067	catype:Mesothelioma
NCT02628067	catype:Pancreatic Neuroendocrine Tumor
NCT02628067	catype:Salivary Gland Carcinoma
NCT02628067	catype:Small bowel Neuroendocrine Tumor
NCT02628067	catype:Small-Cell Lung Carcinoma
NCT02628067	catype:Thyroid Carcinoma
NCT02628067	catype:Vulvar Cancer
NCT02628067	microsatellite_instability:high
NCT02960022	*prior_therapy:Enzalutamide
NCT03093116	(NTRK1:fusion OR NTRK2:fusion OR NTRK3:fusion OR ROS1:fusion)
NCT03093116	ALK:fusion
NCT03175224	(MET:oncogenic_mutation OR MET:alteration)
NCT03424005	NOT ERBB2:amplification; NOT ERBB2:overexpression; NOT ER:positive; *ER:negative; *CD274:protein_expression
NCT03424005	NOT ERBB2:amplification; NOT ERBB2:overexpression; NOT ER:negative; *ER:positive; PIK3CA:oncogenic_mutation
NCT03424005	(ERBB2:amplification OR ERBB2:overexpression OR ERBB2:protein_expression OR ERBB2:low_protein_expression); PIK3CA:oncogenic_mutation
NCT03486873	EXTENSION_STUDY
NCT03821935	catype:Head and neck squamous cell carcinoma
NCT03821935	catype:Hepatocellular carcinoma
NCT03821935	catype:Pancreatic adenocarcinoma
NCT03821935	catype:Triple-negative breast cancer
NCT03821935	catype:Urothelial cancer
NCT03906331	RET:fusion; *Expanded access program
NCT03906331	RET:oncogenic_mutation; NOT RET:amplification; *Expanded access program
NCT03947385	(GNAQ:oncogenic_mutation OR GNA11:oncogenic_mutation OR PRKC:fusion)
NCT04064060	NOT catype:solid tumours
NCT04164199	access:by_invitation_only
NCT04170283	NOT catype:solid tumours
NCT04185883	KRAS:G12C
NCT04221035	catype:Neuroblastoma
NCT04449874	KRAS:G12C; NOT prior_therapy:KRAS_G12C_inhibitor; catype:Colorectal cancer
NCT04449874	KRAS:G12C; NOT prior_therapy:KRAS_G12C_inhibitor; catype:Non-small cell lung cancer
NCT04449874	KRAS:G12C; NOT prior_therapy:KRAS_G12C_inhibitor; catype:Solid tumour
NCT04460456	(ERBB2:amplification OR ERBB2:overexpression OR ERBB2:protein_expression)
NCT04516447	(catype:Ovarian cancer OR catype:Fallopian tube carcinoma OR catype:Peritoneal serous carcinoma); *catype:High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
NCT04606446	(catype:Breast cancer OR catype:Prostate cancer OR catype:Non-small cell lung cancer)
NCT04613596	KRAS:G12C; *NOT prior_therapy:systemic_therapy
NCT04665206	catype:Solid tumour; NOT WWTR1:fusion; NOT WWTR1:WWTR1-CAMTA1_fusion; *(NF2:oncogenic_mutation OR NF2:alteration)
NCT04665206	catype:Solid tumour; NOT NF2:oncogenic_mutation; NOT NF2:alteration; *(WWTR1:fusion OR WWTR1:WWTR1-CAMTA1_fusion)
NCT04857372	catype:Mesothelioma
NCT04857372	catype:Solid tumour; NOT NF2:oncogenic_mutation; NOT NF2:alteration; *(WWTR1:fusion OR WWTR1:WWTR1-CAMTA1_fusion)
NCT04857372	catype:Solid tumour; NOT WWTR1:fusion; NOT WWTR1:WWTR1-CAMTA1_fusion; *(NF2:oncogenic_mutation OR NF2:deletion)
NCT04956640	KRAS:G12C; *NOT prior_therapy:KRAS_G12C_inhibitor
NCT05067283	KRAS:G12C
NCT05086692	*prior_therapy:immune_checkpoint_blockade; (catype:Melanoma OR catype:Non-melanoma skin cancer)
NCT05086692	*(microsatellite_instability:high OR mismatch_repair:deficient)
NCT05198934	KRAS:G12C; catype:Colorectal cancer
NCT05288166	catype:Prostate cancer
NCT05217446	BRAF:V600E; (microsatellite_instability:high OR mismatch_repair:deficient)
NCT05054725	KRAS:G12C; *NOT prior_therapy:KRAS_G12C_inhibitor
NCT03900442	(catype:Multiple myeloma OR catype:Peripheral T-cell lymphoma OR catype:Colorectal cancer OR catype:Pancreatic adenocarcinoma); *Unknown status
NCT03900442	catype:Gastric cancer; *catype:Diffuse gastric cancer; *Unknown status
NCT05182931	(BRAF:V600E OR NRAS:oncogenic_mutation); NOT catype:Anaplastic thyroid cancer
NCT05152147	(ERBB2:amplification OR ERBB2:overexpression)
NCT05364073	catype:Non-small cell lung cancer
NCT05311176	(catype:Gastroesophageal junction adenocarcinoma OR Gastroesophageal adenocarcinoma OR catype:Gastric Cancer); *(ERBB2:overexpression OR ERBB2:amplification); *prior_therapy:Trastuzumab
NCT05440786	catype:Ewings sarcoma
NCT05388669	EGFR:oncogenic_mutation; *prior_therapy:Osimertinib
NCT05315700	NOT EGFR:T790M; (EGFR:exon_20_insertion OR ERBB2:exon_20_insertion OR ERBB2:amplification OR ERBB2:overexpression)
NCT05187624	EGFR:vIII; NOT_RECRUITING
NCT05307705	PIK3CA:H1047R
NCT05269316	NOT catype:Central nervous system cancer; *NOT_RECRUITING_IN_WA_NSW
NCT05253651	(ERBB2:amplification OR ERBB2:overexpression)
NCT05480865	KRAS:G12C
NCT05425940	catype:Colorectal cancer; NOT prior_therapy:Regorafenib; NOT prior_therapy:Trifluridine/Tipiracil; NOT prior_therapy:TAS-102; NOT prior_therapy:Lonsurf
NCT05609370	catype:Colorectal cancer; NOT MSI:high; NOT MMR:deficient
NCT05512377	MDM2:amplification; NOT TP53:oncogenic_mutation; (catype:Urothelial carcinoma OR catype:Lung adenocarcinoma); *NOT catype:Urothelial carcinoma
NCT05614739	FGFR3:alteration
NCT05501886	NOT prior_therapy:PI3K_inhibitor; NOT prior_therapy:AKT_inhibitor; NOT prior_therapy:mTOR_inhibitor
NCT05555732	*NOT prior_therapy:systemic_therapy; catype:Non-squamous non-small cell lung cancer
NCT05384626	(ALK:oncogenic_mutation OR ALK:fusion)
NCT05789082	KRAS:G12C; *NOT prior_therapy:systemic_therapy
NCT05654623	NOT prior_therapy:ARV-471; NOT prior_therapy:Fulvestrant; NOT prior_therapy:mTOR_inhibitor; NOT prior_therapy:PI3K_inhibitor; NOT prior_therapy:AKT_inhibitor; NOT prior_therapy:PARP_inhibitor
NCT04862663	NOT prior_therapy:selective_estrogen_receptor_degrader; *NOT prior_therapy:CDK4/6_inhibitor; NOT prior_therapy:mTOR_inhibitor; NOT prior_therapy:PI3K_inhibitor; NOT prior_therapy:AKT_inhibitor; *NOT prior_therapy:Fulvestrant; *NOT prior_therapy:selective_estrogen_receptor_degrader; *NOT prior_therapy:PI3K_inhibitor; *NOT prior_therapy:AKT_inhibitor; *NOT prior_therapy:mTOR_inhibitor
NCT05501886	NOT prior_therapy:selective_estrogen_receptor_degrader; NOT prior_therapy:mTOR_inhibitor; NOT prior_therapy:PI3K_inhibitor; NOT prior_therapy:AKT_inhibitor; NOT prior_therapy:Eribulin; NOT ERBB2:amplification; NOT ERBB2:overexpression
NCT05118789	ROS1:fusion
NCT05338970	EGFR:oncogenic_mutation
NCT04771130	*NOT prior_therapy:BCL2_inhibitor; *NOT prior_therapy:Azacitidine
NCT05910827	*NOT KRAS:oncogenic_mutation; *NOT PIK3CA:oncogenic_mutation; *NOT BRAF:oncogenic_mutation; *NOT PTEN:deletion; *NOT PTEN:oncogenic_mutation; *NOT MET:amplification; catype:Lung squamous cell carcinoma; *prior_therapy:cancer_therapy,PD-1/PD-L1-targeting; NOT prior_therapy:docetaxel; NOT prior_therapy:cetuximab; *NOT prior_therapy:cancer_therapy,ERBB3-targeting; *prior_therapy:systemic_therapy
NCT05286801	(SMARCB1:loss OR SMARCB1:oncogenic_mutation OR SMARCB1:loss_of_protein_expression OR SMARCA4:loss OR SMARCA4:oncogenic_mutation OR SMARCA4:loss_of_protein_expression); *PAEDIATRIC_TRIAL
NCT05646862	PIK3CA:oncogenic_mutation; NOT ERBB2:amplification; catype:Breast cancer; NOT catype:HER2-positive breast cancer
NCT04879329	*HER2:positive; *ERBB2:protein_expression; *ERBB2:overexpression
NCT04789096	*HER2:positive; *ERBB2:protein_expression; *ERBB2:overexpression; *prior_therapy:Trastuzumab; *prior_therapy:Pertuzumab; *prior_therapy:taxane; *prior_therapy:Trastuzumab emtansine; *NOT prior_therapy:Pembrolizumab; *NOT prior_therapy:Nivolumab; *NOT prior_therapy:Atezolizumab; *NOT prior_therapy:Durvalumab; *NOT prior_therapy:Avelumab; *NOT prior_therapy:Ipilimumab; *NOT prior_therapy:Tremelimumab
NCT04924075	*NOT KIT:oncogenic_mutation; *NOT PDGFRB:oncogenic_mutation; catype:Gastrointestinal stromal tumour
NCT04924075	VHL:oncogenic_mutation; (catype:Pheochromocytoma OR catype:Paraganglioma)
NCT04924075	catype:Solid tumour; (EPAS1:alteration OR FH:alteration OR SDHA:alteration OR SDHB:alteration OR SDHC:alteration OR SDHD:alteration OR SDHAF2:alteration OR EGLN1:alteration OR EGLN:alteration OR MDH2:alteration OR ELOC:alteration OR TCEB1:alteration); *NOT VHL:oncogenic_mutation
NCT05261399	catype:Non-small cell lung cancer; EGFR:oncogenic_mutation; *NOT prior_therapy:Osimertinib
NCT05876754	catype:Cholangiocarcinoma; IDH1:R132_mutation; *NOT prior_therapy:IDH1_R132_inhibitor
NCT05487235	catype:Solid tumour; sensitive_to:GDC-1971
NCT05487235	catype:Non-small cell lung cancer; *sensitive_to:GDC-1971; *NOT prior_therapy:systemic_therapy
NCT05487235	catype:Head and neck squamous cell carcinoma; *sensitive_to:GDC-1971; *NOT prior_therapy:systemic_therapy
NCT05487235	catype:Melanoma; NOT BRAF:oncogenic_mutation; *sensitive_to:GDC-1971; *prior_therapy:anti-PD-1_monoclonal_antibody; NOT catype:Mucosal melanoma; NOT catype:Uveal melanoma
NCT05919537	NRG1:fusion
NCT05919537	NOT NRG1:fusion; ERBB3:extracellular_domain_mutation
NCT05743036	BRAF:V600E; catype:Colorectal cancer
NCT05611931	NOT TP53:oncogenic_mutation
NCT05647122	catype:Non-small cell lung cancer; EGFR:oncogenic_mutation
NCT05647122	catype:Non-small cell lung cancer; NOT EGFR:oncogenic_mutation
NCT05647122	catype:Head and neck squamous cell carcinoma
NCT04928846	NOT EGFR:oncogenic_mutation; catype:Non-small cell lung cancer
NCT05245968	catype:Gastrointestinal stromal tumour
NCT05383352	catype:Pancreatic adenocarcinoma
NCT05759728	catype:Colorectal adenocarcinoma
NCT05513703	catype:Non-small cell lung cancer; NOT catype:Lung squamous cell carcinoma; NOT EGFR:oncogenic_mutation; NOT ALK:fusion; NOT ROS1:fusion; NOT BRAF:oncogenic_mutation; *NOT prior_therapy:systemic_therapy; *MET:amplification
NCT05338970	catype:Non-squamous non-small cell lung cancer; (EGFR:L858R OR EGFR:exon_19_deletion)
ACTRN12623000223639	catype:Pancreatic adenocarcinoma
NCT04612751	NOT prior_therapy:systemic_therapy
NCT04612751	NOT prior_therapy:anti-PD-1_monoclonal_antibody
NCT05555732	NOT EGFR:oncogenic_mutation; NOT ALK:fusion; NOT ROS1:fusion; NOT NTRK1:fusion; NOT NTRK2:fusion; NOT NTRK3:fusion; NOT BRAF:V600E; NOT BRAF:class_2_mutation; NOT BRAF:class_3_mutation; NOT RET:fusion; NOT MET:exon_14_skipping_mutation; NOT prior_therapy:systemic_therapy; NOT prior_therapy:anti-Trop2_monoclonal_antibody; NOT prior_therapy:anti-PD-1_monoclonal_antibody; NOT prior_therapy:anti-PD-L1_monoclonal_antibody
NCT05328908	catype:Colorectal adenocarcinoma
NCT04985721	*sensitive_to:Pamiparib
NCT05067283	catype:Solid tumour; NOT catype:Non-small cell lung cancer; KRAS:G12C; prior_therapy:systemic_therapy
NCT05067283	catype:Non-small cell lung cancer; NOT prior_therapy:systemic_therapy; KRAS:G12C
NCT05067283	catype:Colorectal cancer; NOT prior_therapy:systemic_therapy; KRAS:G12C
NCT05919537	(ERBB3:V104M OR ERBB3:V104L OR ERBB3:G284R OR ERBB3:D297Y OR ERBB3:D297V OR ERBB3:A232V); NOT KRAS:oncogenic_mutation; NOT PIK3CA:oncogenic_mutation; NOT BRAF:oncogenic_mutation; NOT PTEN:deletion; NOT PTEN:oncogenic_mutation; NOT MET:amplification
NCT05498428	catype:Non-small cell lung cancer; (EGFR:exon_19_deletion OR EGFR:L858R OR EGFR:exon_20_insertion)
NCT05388669	catype:Non-small cell lung cancer; (EGFR:exon_19_deletion OR EGFR:L858R)
NCT05580770	catype:Melanoma; NRAS:oncogenic_mutation
NCT05580770	catype:Non-small cell lung cancer; KRAS:oncogenic_mutation
NCT05580770	(catype:Non-small cell lung cancer OR catype:Melanoma); (BRAF:class_2_mutation OR BRAF:class_3_mutation)
NCT04985721	(ATM:oncogenic_mutation OR CDK12:oncogenic_mutation OR PALB2:oncogenic_mutation OR ARID1A:oncogenic_mutation OR ATRX:oncogenic_mutation OR BLM:oncogenic_mutation OR BARD1:oncogenic_mutation OR BRIP1:oncogenic_mutation OR CHEK1:oncogenic_mutation OR CHEK2:oncogenic_mutation OR FANCA:oncogenic_mutation OR FANCF:oncogenic_mutation OR FANCG:oncogenic_mutation OR FANCI:oncogenic_mutation OR FANCL:oncogenic_mutation OR FANCM:oncogenic_mutation OR MSH2:oncogenic_mutation OR NBN:oncogenic_mutation OR RAD50:oncogenic_mutation OR RAD51C:oncogenic_mutation OR RAD51D:oncogenic_mutation OR WRN:oncogenic_mutation OR mutational_signature:SBS3 OR loss_of_heterozygozity_score:high OR homologous_recombination_score:high)
NCT04985721	(BRCA1:oncogenic_mutation OR BRCA2:oncogenic_mutation)
NCT05919537	NRG1:fusion
NCT05919537	NOT NRG1:fusion; ERBB3:oncogenic_mutation; *(ERBB3:V104M OR ERBB3:V104L OR ERBB3:G284R OR ERBB3:D297V OR ERBB3:D297Y OR ERBB3:A232V); *NOT KRAS:oncogenic_mutation; *NOT PIK3CA:oncogenic_mutation; *NOT BRAF:oncogenic_mutation; *NOT PTEN:oncogenic_mutation; *NOT PTEN:loss; *NOT MET:amplification
NCT05694936	*NOT prior_therapy:systemic_therapy
NCT05894239	PIK3CA:oncogenic_mutation; *(ERBB2:amplification OR ERBB2:overexpression); *(PIK3CA:H1047L OR PIK3CA:H1047R OR PIK3CA:H1047Y OR PIK3CA:E545A OR PIK3CA:E545D OR PIK3CA:E545G OR PIK3CA:E545K OR PIK3CA:Q546E OR PIK3CA:Q546E OR PIK3CA:Q546R OR PIK3CA:E542K OR PIK3CA:C420R OR PIK3CA:Q88Q OR PIK3CA:N345K OR PIK3CA:M1043I OR PIK3CA:G1049R)
NCT05872295	catype:Breast cancer; *(ERBB2:amplification OR ERBB2:overexpression ERBB2:protein_expression OR OR ERBB2:low_protein_expression)
NCT05872295	(catype:Gastric cancer OR catype:Gastroesophageal adenocarcinoma); *(ERBB2:amplification OR ERBB2:overexpression OR ERBB2:protein_expression OR ERBB2:low_protein_expression); prior_therapy:systemic_therapy
NCT05872295	catype:Solid tumour; NOT Breast cancer; NOT Gastric cancer; NOT Gastroesophageal adenocarcinoma; *(ERBB2:amplification OR ERBB2:protein_expression OR ERBB2:overexpression OR ERBB2:low_protein_expression OR ERBB2:oncogenic_mutation)
NCT05577416	NOT prior_therapy:systemic_therapy; catype:Low-grade glioma
NCT04929223	catype:Colorectal adenocarcinoma; *(microsatellite_instability:high OR mismatch_repair:deficient); *NOT_RECRUITING
NCT04929223	catype:Colorectal adenocarcinoma; KRAS:G12C
NCT05388669	EGFR:oncogenic_mutation
NCT04895709	*NOT prior_therapy:Docetaxel
NCT05348577	*NOT prior_therapy:Docetaxel; *NOT prior_therapy:AKT_inhibitor
NCT05544552	FGFR3:alteration
NCT06024174	KRAS:G12C; (catype:Non-small cell lung cancer OR catype:Pancreatic adenocarcinoma OR catype:Biliary tract cancer OR catype:Colorectal cancer); NOT BRAF:V600; NOT PTPN:oncogenic_mutation; NOT KRAS:Q61
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; NOT ERBB2:amplification; *CLOSED_TO_RECRUITMENT
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; NOT ERBB2:amplification; *CLOSED_TO_RECRUITMENT; sensitive_to:Ipatasertib; *NOT prior_therapy:AKT_inhibitor
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; NOT ERBB2:amplification; *CLOSED_TO_RECRUITMENT; sensitive_to:Inavolisib; *NOT prior_therapy:AKT_inhibitor; *NOT prior_therapy:PI3K_alpha_inhibitor; *NOT prior_therapy:MTOR_inhibitor
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; (ERBB2:amplification OR ERBB2:overexpression)
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; *NOT prior_therapy:MTOR_inhibitor; *CLOSED_TO_RECRUITMENT
NCT04802759	catype:Breast cancer; *ESR1:protein_expression; sensitive_to:Atezolizumab; *NOT prior_therapy:anti-CD137_agonistic_antibody; *NOT prior_therapy:anti-CTLA-4_monoclonal_antibody; *NOT prior_therapy:anti-PD-1_monoclonal_antibody; *NOT prior_therapy:anti-PD-L1_monoclonal_antibody; *CLOSED_TO_RECRUITMENT
NCT05417594	(BRCA1:oncogenic_mutation OR BRCA2:oncogenic_mutation OR PALB2:oncogenic_mutation OR RAD51C:oncogenic_mutation OR RAD51D:oncogenic_mutation)
NCT05954871	catype:Colorectal cancer; NOT KRAS:oncogenic_mutation; NOT BRAF:V600E; NOT NRAS:oncogenic_mutation; NOT EGFR:oncogenic_mutation; *CRC_COHORT_NO_SLOTS
NCT05954871	catype:Non-small-cell lung cancer; (EGFR:L858R OR EGFR:exon_19_deletion); NOT KRAS:oncogenic_mutation; NOT NRAS:oncogenic_mutation; NOT BRAF:V600E; *prior_therapy:Osimertinib
NCT06119581	KRAS:G12C; *NOT prior_therapy:systemic_therapy; catype:Non-small cell lung cancer
NCT05462717	KRAS:G12C
NCT05328908	catype:Colorectal adenocarcinoma; NOT prior_therapy:Regorafenib; NOT prior_therapy:Trifluridine; NOT prior_therapy:immune_checkpoint_blockade; *prior_therapy:fluoropyrimidine; *prior_therapy:Oxaliplatin; *prior_therapy:Irinotecan; NOT prior_therapy:Lonsurf
NCT05775289	*NOT prior_therapy:systemic_therapy; NOT_RECRUITING
NCT05450692	NOT EGFR:exon_19_deletion; NOT EGFR:L858R; NOT EGFR:oncogenic_mutation; NOT ALK:fusion; *(prior_therapy:anti-PD-1_monoclonal_antibody OR prior_therapy:anti-PD-L1_monoclonal_antibody); *(prior_therapy:Carboplatin OR prior_therapy:Cisplatin)
NCT05867121	catype:Non-small cell lung cancer
NCT05867121	catype:Gastric cancer
NCT05867121	catype:Pancreatic adenocarcinoma
NCT05909397	NOT prior_therapy:CDK4/6_inhibitor; NOT prior_therapy:Fulvestrant; NOT prior_therapy:Elacestrant; NOT prior_therapy:selective_estrogen_receptor_degrader; NOT prior_therapy:SERCA; NOT prior_therapy:CERAN
NCT05696626	ESR1:oncogenic_mutation
NCT05208047	catype:Gastrointestinal stromal tumour
NCT05330429	catype:Colorectal cancer
ACTRN12619000566134	catype:Colorectal cancer
NCT04524871	catype:Hepatocellular carcinoma
NCT06036836	catype:Cutaneous squamous cell carcinoma; *NOT prior_therapy:systemic_therapy
NCT06036836	catype:Endometrial carcinoma; mismatch_repair:deficient
NCT06036836	catype:Endometrial carcinoma; microsatellite_instability:high
NCT05607550	EGFR:exon_20_insertion
NCT05650879	ERBB2:exon_20_insertion
NCT06016738	*prior_therapy:CDK4/6_inhibitor; NOT prior_therapy:Eribulin; NOT prior_therapy:Elacestrant
NCT06105632	NOT ERBB2:amplification; *prior_therapy:CDK4/6_inhibitor
NCT06179160	KRAS:G12D
NCT06194877	(KRAS:oncogenic_mutation OR NRAS:oncogenic_mutation OR BRAF:oncogenic_mutation); (catype:Colorectal adenocarcinoma OR catype:Pancreatic adenocarcinoma)
NCT04585750	TP53:Y220C; *NOT KRAS:oncogenic_mutation
NCT05094336	*CDKN2A:deletion; MTAP:deletion; *(catype:Lung squamous cell carcinoma OR catype:Gastric cancer OR catype:Gastroesophageal cancer); *(info:panel:AVENIO OR info:panel:FM1 CDx); 
NCT05094336	*CDKN2A:deletion; MTAP:deletion; catype:Pancreatic adenocarcinoma; *NO_SLOTS_AVAILABLE
NCT05975073	(MTAP:deletion OR MTAP:loss_of_protein_expression)
NCT06065748	*NOT (ERBB2:amplification OR ERBB2:overexpression); *ESR1:protein_expression; ESR1:oncogenic_mutation; NOT prior_therapy:selective_estrogen_receptor_degrader; NOT prior_therapy:SERCA; NOT prior_therapy:CERAN
NCT05867121	*(catype:Non-small cell lung carcinoma OR catype:Gastric cancer OR catype:Pancreatic adenocarcinoma)
NCT06064877	catype:Head and neck squamous cell carcinoma; *(prior_therapy:Carboplatin OR prior_therapy:Cisplatin); *(prior_therapy:anti-PD-1_monoclonal_antibody OR prior_therapy:anti-PD-L1_monoclonal_antibody)
NCT06188702	*MTAP:deletion; NOT catype:Central nervous system cancer; *(info:panel:AVENIO OR info:panel:FM1 CDx)
NCT05907304	(KRAS:Q61 OR NRAS:Q61 OR HRAS:Q61); *NOT prior_therapy:ERK_inhibitor; *NOT prior_therapy:MEK_inhibitor; *NOT prior_therapy:RAF_inhibitor; *NOT prior_therapy:RAS_inhibitor
NCT06003621	NOT catype:Non-small cell lung cancer
NCT06031441	*MOA_UNKNOWN
NCT05805501	catype:Clear cell renal cell carcinoma
NCT04644068	sensitive_to_drug_class:PARP_inhibitor
NCT06151574	ERBB2:kinase_domain_mutation; catype:Non-small cell lung cancer
NCT06372574	*MAGEA4:protein_expression
NCT06326411	catype:Melanoma; (NRAS:oncogenic_mutation OR BRAF:oncogenic_mutation)
NCT06326411	catype:Solid tumour; NOT catype:Melanoma; (NRAS:oncogenic_mutation OR BRAF:oncogenic_mutation OR KRAS:oncogenic_mutation)
NCT06326411	catype:Glioma; BRAF:oncogenic_mutation
NCT06018337	(ERBB2:protein_expression OR ERBB2:low_protein_expression); NOT ERBB2:amplification; NOT ERBB2:overexpression
NCT06326411	(BRAF:K601E OR BRAF:K601N OR BRAF:K601T OR BRAF:K601Q OR BRAF:N486_A489delinsK OR BRAF:N486_P490del OR BRAF:G469A OR BRAF:G469V OR BRAF:G469R OR BRAF:G649S OR BRAF:fusion OR BRAF:L597Q OR BRAF:L597R OR BRAF:L597S OR BRAF:L597V)
NCT06326411	(BRAF:D287H OR BRAF:G466A OR BRAF:G466 OR BRAF:G466 OR BRAF:G466E OR BRAF:G466V OR BRAF:G466R OR BRAF:G469E OR BRAF:N581I OR BRAF:N581S OR BRAF:N581T OR BRAF:N581Y OR BRAF:N581K OR BRAF:D594A OR BRAF:D594G OR BRAF:D594H OR BRAF:D594N OR BRAF:D594E OR BRAF:D594Y OR BRAF:D594V OR BRAF:D596D OR BRAF:D596R OR BRAF:D596C OR BRAF:D596V)
NCT06326411	(NRAS:Q61 OR NRAS:G12 OR NRAS:G13)
NCT06326411	(KRAS:Q61 OR KRAS:G12 OR KRAS:G13)
NCT05203172	BRAF:V600E
NCT04686305	catype:Non-small cell lung cancer; *NOT prior_therapy:systemic_therapy; *ERBB2:overexpression; *NOT ERBB2:oncogenic_mutation
NCT06162572	catype:Non-small cell lung cancer; *NOT prior_therapy:systemic_therapy; *CD274:protein_expression; NOT EGFR:oncogenic_mutation; NOT ALK:fusion; NOT ROS1:alteration; NOT prior_therapy:cancer_therapy,PD-1/PD-L1-targeting
NCT06208657	trial_type:paediatric
NCT03906669	trial_type:curative
NCT06343402	KRAS:G12C; (catype:Non-small cell lung cancer OR catype:Colorectal adenocarcinoma)
NCT06346067	catype:Melanoma; NRAS:oncogenic_mutation
NCT05352672	*NOT prior_therapy:systemic_therapy
NCT06127407	catype:Chondrosarcoma
NCT05609968	*NOT prior_therapy:systemic_therapy
NCT05215340	*NOT prior_therapy:systemic_therapy
NCT05216432	PIK3CA:oncogenic_mutation
NCT06252649	KRAS:G12C; *NOT prior_therapy:systemic_therapy
NCT06599502	KRAS:G12D
NCT06659341	KRAS:G12C
NCT06497556	KRAS:G12C; catype:Non-small cell lung cancer
NCT06345729	KRAS:G12C; catype:Non-small cell lung cancer
NCT06119581	KRAS:G12C; catype:Non-small cell lung cancer
NCT05789082	KRAS:G12C; catype:Non-small cell lung cancer; *NOT prior_therapy:systemic_therapy
NCT05410145	KRAS:G12C; catype:Non-small cell lung cancer
NCT05907304	(KRAS:Q61 OR HRAS:Q61 OR NRAS:Q61)
NCT05727176	FGFR2:fusion; catype:Cholangiocarcinoma
NCT05987332	*NOT HLA-A2:A*02:01
NCT05536141	catype:Clear cell renal cell carcinoma
NCT05581004	(catype:Non-small cell lung cancer OR catype:Head and neck squamous cell carcinoma OR catype:Melanoma OR catype:Gastric cancer); *HNSCC_COHORT_FILLED
NCT05800665	*prior_therapy:AR-targeted_agent,next_generation; catype:Prostate cancer
NCT06509906	catype:Colorectal adenocarcinoma
NCT06560645	(SMARCA4:oncogenic_mutation OR SMARCA4:deletion)
NCT06589596	(MTAP:deletion OR MTAP:loss_of_protein_expression); *(info:panel:AVENIO OR info:panel:FM1 CDx)
NCT06585488	KRAS:alteration
NCT05867251	*catype:Breast cancer
NCT05867251	CCNE1:amplification; *(catype:Ovarian cancer OR catype:Fallopian tube carcinoma OR catype:Peritoneal serous carcinoma)
NCT06581432	ERBB2:alteration
NCT06625775	catype:Breast cancer; (ERBB2:overexpression OR ERBB2:amplification)
NCT06625775	catype:Breast cancer; ER:positive
NCT06625775	catype:Colorectal cancer; KRAS:oncogenic_mutation
NCT06625775	catype:Non-small cell lung cancer; KRAS:oncogenic_mutation
NCT06533059	AKT1:E17K; NOT KRAS:oncogenic_mutation; NOT NRAS:oncogenic_mutation; NOT HRAS:oncogenic_mutation; NOT BRAF:oncogenic_mutation; *NOT prior_therapy:PI3K_inhibitor; *NOT prior_therapy:mTOR_inhibitor
NCT06380751	catype:Breast cancer; (BRCA1:oncogenic_mutation OR BRCA2:oncogenic_mutation OR PALB2:oncogenic_mutation); ER:positive: HER2:negative
